Author

B. Ogretmen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Akyol· 1 shared A. Isik· 1 shared A. Uner· 1 shared C. Lin· 1 shared D. Buyco· 1 shared D. Gautheret· 1 shared D. Thieffry· 1 shared E. Scorletti· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Akyol

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer

O. Saatci, R. Alam, K.-T. Huynh-Dam, A. Isik, M. Uner, N. Belder, P. G. Ersan, M. Cetin, U. M. Tokat, M. E. Gedik, H. Bal, O. S. Sahin, Y. Riazalhosseini, D. Thieffry, D. Gautheret, , O. Sahin

This study identifies LINC00152 as a driver of tamoxifen resistance in ER+ breast cancer by inhibiting ferroptosis, and shows that targeting LINC00152 restores sensitivity to tamoxifen.

bioRxiv · Nov 5, 2023Cancer Biology

Ceramide synthase 6 (CerS6) promotes alcohol-induced fatty liver by promoting metabolic dysfunction and upregulating lipid droplet-associated proteins

S. Jeon, E. Scorletti, D. Buyco, C. Lin, Y. Saiman, J. Martin, R. Hooks, B. Ogretmen, J. Argemi, L. Melo, R. Bataller, R. M. Carr

This study shows that deleting CerS6 reduces alcohol-induced fatty liver and improves glucose homeostasis in mice, and links CerS6 expression to ALD progression in humans.

bioRxiv · Nov 3, 2022 · PreprintPathology